Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular...

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge, necessitating novel systemic therapies.
• Pin1, a key regulator of miRNA biogenesis, has been identified as a potential therapeutic target for HCC.
• Previous inhibitor API-1 showed promise but had limitations in chemical stability and pharmacokinetics.

Purpose of the Study:

• To design and synthesize novel Pin1 inhibitors with improved properties for HCC treatment.
• To evaluate the efficacy and safety of the newly developed inhibitor API-32 against HCC.
• To investigate the mechanism of action of API-32 in inhibiting Pin1 activity and downstream signaling.

Main Methods:

• Synthesis of diverse 6-O-benzylguanine derivatives.
• Biochemical assays to confirm Pin1 inhibition and interaction with the PPIase domain.
• In vitro studies assessing the effects of API-32 on HCC cell proliferation and migration.
• In vivo studies using mouse models to evaluate tumor growth inhibition and toxicity.

Main Results:

• API-32, a novel Pin1 inhibitor, was successfully designed and synthesized.
• API-32 demonstrated superior chemical stability and pharmacokinetic properties compared to API-1.
• API-32 directly inhibited Pin1 activity by interacting with its PPIase domain.
• API-32 significantly suppressed HCC cell proliferation and migration in vitro.
• API-32 showed enhanced inhibition of HCC tumor growth in vivo with no obvious toxicity.

Conclusions:

• API-32 is a potent Pin1 inhibitor with enhanced stability and pharmacokinetic profiles, outperforming API-1.
• API-32 effectively suppresses HCC progression through Pin1 inhibition.
• API-32 represents a promising drug candidate for the treatment of hepatocellular carcinoma.